Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive
Status:
Suspended
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase IIb multicenter, open-label, non-comparative trial of continuous daily oral
10 mg of ulipristal acetate (UPA) to evaluate its contraceptive efficacy as the primary
method of contraception.
Phase:
Phase 2
Details
Lead Sponsor:
Health Decisions
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)